Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Anderson

Showing results (241-250 of 249) with videos related to

Pageof 25
Sort By:
You have reached the last page of results.This site can display upto 249 results.
Journal of the International AIDS Society|August 21, 2025
A cross-sectional study evaluating the frequency of HIV drug resistance mutations among individuals diagnosed with HIV-1 in tenofovir disoproxil fumarate-based pre-exposure prophylaxis rollout programmes in Kenya, Zimbabwe, Eswatini and South AfricaUrvi M Parikh, Lauren D Kudrick, Lisa Levy, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal AntibodySrilatha Edupuganti, Nyaradzo Mgodi, Shelly T Karuna, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2023
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083Mark A Marzinke, Jessica M Fogel, Zhe Wang, et al.
The Journal of Infectious Diseases|March 18, 2022
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084Susan H Eshleman, Jessica M Fogel, Estelle Piwowar-Manning, et al.
The Lancet. HIV|November 12, 2023
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trialRaphael J Landovitz, Brett S Hanscom, Meredith E Clement, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Viral and Host Mediators of Non-Suppressible HIV-1 ViremiaAbbas Mohammadi, Behzad Etemad, Xin Zhang, et al.
Nature Medicine|November 13, 2023
Viral and host mediators of non-suppressible HIV-1 viremiaAbbas Mohammadi, Behzad Etemad, Xin Zhang, et al.
Lancet (London, England)|April 4, 2022
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trialSinead Delany-Moretlwe, James P Hughes, Peter Bock, et al.
The New England Journal of Medicine|November 25, 2010
Preexposure chemoprophylaxis for HIV prevention in men who have sex with menRobert M Grant, Javier R Lama, Peter L Anderson, et al.
Pageof 25

Showing results (241-250 of 249) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 249 results.
Journal of the International AIDS Society|August 21, 2025
A cross-sectional study evaluating the frequency of HIV drug resistance mutations among individuals diagnosed with HIV-1 in tenofovir disoproxil fumarate-based pre-exposure prophylaxis rollout programmes in Kenya, Zimbabwe, Eswatini and South AfricaUrvi M Parikh, Lauren D Kudrick, Lisa Levy, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal AntibodySrilatha Edupuganti, Nyaradzo Mgodi, Shelly T Karuna, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2023
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083Mark A Marzinke, Jessica M Fogel, Zhe Wang, et al.
The Journal of Infectious Diseases|March 18, 2022
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084Susan H Eshleman, Jessica M Fogel, Estelle Piwowar-Manning, et al.
The Lancet. HIV|November 12, 2023
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trialRaphael J Landovitz, Brett S Hanscom, Meredith E Clement, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2023
Viral and Host Mediators of Non-Suppressible HIV-1 ViremiaAbbas Mohammadi, Behzad Etemad, Xin Zhang, et al.
Nature Medicine|November 13, 2023
Viral and host mediators of non-suppressible HIV-1 viremiaAbbas Mohammadi, Behzad Etemad, Xin Zhang, et al.
Lancet (London, England)|April 4, 2022
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trialSinead Delany-Moretlwe, James P Hughes, Peter Bock, et al.
The New England Journal of Medicine|November 25, 2010
Preexposure chemoprophylaxis for HIV prevention in men who have sex with menRobert M Grant, Javier R Lama, Peter L Anderson, et al.
Pageof 25